肿瘤细胞治疗研究
英文原题：Fucoidan potentiates CAR NK cell-mediated antitumor efficacy against non-Hodgkin lymphoma via NRF2.
Fucoidan potentiates CAR NK cell-mediated antitumor efficacy against non-Hodgkin lymphoma via NRF2.
尽管岩藻多糖（FO）与抗癌药物之间的协同效应潜力已在众多临床前研究中得到证实，但FO在细胞免疫治疗中的潜在应用仍很大程度上未被探索。
尽管岩藻多糖（FO）与抗癌药物之间的协同效应潜力已在大量临床前研究中得到证实，但FO在细胞免疫治疗中的潜在应用仍 largely 未被探索。CAR NK细胞疗法已成为癌症免疫治疗中一种有前景的策略。在本研究中，我们探讨了FO在非霍奇金淋巴瘤（NHL）CAR NK细胞治疗中的作用。我们的研究结果揭示，FO通过增强NRF2活性来提升CAR NK细胞的功能。FO改善了细胞能量代谢并提高了CAR NK细胞的抗氧化活性。值得注意的是，经FO处理的CAR NK细胞对NHL细胞表现出增强的细胞毒性，并提高了细胞因子分泌。此外，FO延长了CAR NK细胞在组织中的持久性。静脉给予CD19-CAR NK细胞联合FO，可有效清除腹腔荷瘤小鼠体内的NHL癌细胞，并显著延长其生存期。这些结果凸显了FO在基于CAR NK细胞的疗法中的支持作用，并提示其作为临床细胞免疫治疗佐剂的潜力。
Although the potential for synergistic effects between fucoidan (FO) and anticancer drugs has been documented in numerous preclinical studies, FO's potential application in cellular immunotherapy remains largely unexplored. CAR NK cell therapy has emerged as a promising strategy in cancer immunotherapy. In this study, we investigated the role of FO in CAR NK cell therapy for non-Hodgkin lymphoma (NHL). Our findings reveal that FO enhances the functionality of CAR NK cells by augmenting NRF2 activity. FO improved cellular energetic metabolism and increased antioxidant activity of CAR NK cells. Notably, FO-treated CAR NK cells demonstrated enhanced cytotoxicity against NHL cells and elevated cytokine secretion. Additionally, FO prolonged the persistence of CAR NK cells in tissues. Intravenous administration of CD19-CAR NK cells combined with FO effectively eradicated NHL cancer cells in intraperitoneally tumor-bearing mice and significantly extended their survival. These results highlight the supportive role of FO in CAR NK cell-based therapies and suggest its potential as an adjuvant in clinical cellular immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
